After stent, NPPA starts process to cap other medical devices

Next on the radar: lenses and ortho implants; Pharma lobbies wants representation in price fixing

Veena Mani  |  New Delhi 

After capping coronary stents, the National Pharmaceutical Pricing Authority (NPPA) gears up for price control of other medical devices. The NPPA met intra-ocular lens manufacturers today to discuss the matter. They will subsequently meet orthopaedic implant manufacturers this week. Both these categories of devices are under the pricing regulator's radar to bring them under price control. Capping prices of coronary stents was the first move in slashing prices of medical devices. In February this year, the regulator slashed the prices of coronary stents by 85 per cent. This event ...

TO READ THE FULL STORY, SUBSCRIBE NOW AT JUST Rs 149 A MONTH

Key stories on business-standard.com are available to premium subscribers only.

LOGIN

EMAIL / USER NAME
PASSWORD
REMEMBER ME Forgot password?
LOGIN

Not a member yet ? Resister Now

Connect using any below

  • Don't lose the opportunity of saving $26.77 per month
  • Don't lose the opportunity of saving $26.77 per month
Total Amount
Rs. 0.00
To proceed, kindly select a subscription package

WHAT YOU GET

On Business Standard Digital

  • Access your subscription from anywhere. Be it your computer, tablet or smartphone using a browser or the App, Your Choice.
  • Access to exclusive content, features, opinions and comment, hand-picked by our editors, just for you.
  • Pick your 5 favourite companies. Get all the news upates at the end of each day through E-Mail.
  • Pick the industry that you want to track. And get a daily news letter specific to that industry. Cut out the clutter.
  • And stay on top of your investments. Track stock prices in your portfolio
  • Access 18 years of archival data

On Digital

  • Seamless access to WSJ.com with your Business Standard digital account.
  • Experience the best of the Journal's reporting, video and interactive features.
  • Read about the people and events shaping business, finance, technology, politics, technology and culture.
  • Stay informed with newsletters - an easy way to get WSJ content straight to your inbox - making life easier on your busiest days.
  • More business executives read the Journal globally than any other publication.
*Note :
Our Partners are proud to be associated with this initiative and will contribute Rs 100 x 6 months thereafter, standard rate of Rs 149 will be charged.
Offer valid for Indian residents only
Requires you to share personal information like PAN, Date of Birth, and Income.
*Annual saving on WSJ subscription price of US$ 347.88 (12 months @ US$ 28.99 per month)
* 1US$ = 67.50 INR.
*Please note that this offer is not valid if you are/were a registered/existing user on WSJ Digital

After stent, NPPA starts process to cap other medical devices

Next on the radar: lenses and ortho implants; Pharma lobbies wants representation in price fixing

After capping coronary stents, the National Pharmaceutical Pricing Authority (NPPA) gears up for price control of other medical devices. The NPPA met intra-ocular lens manufacturers today to discuss the matter. They will subsequently meet orthopaedic implant manufacturers this week. Both these category of devices are under the radar of the pricing regulator to bring it under price control.Capping prices of coronary stents was the first move in slashing prices of medical devices. In February this year, the pricing regulator slashed the prices of coronary stents by 85%.This event brought about a change in the thinking of the medical device manufacturers. The CEO of a multi-national device maker said, "The price cap on coronary stents shook us." "The NPPA brought down the price of stents by 85% in one go. We would rather opt for self- regulation than having the NPPA reduce prices like this," he said.The domestic manufacturers of medical devices have written to the Department of ... After capping coronary stents, the National Pharmaceutical Pricing Authority (NPPA) gears up for price control of other medical devices. The NPPA met intra-ocular lens manufacturers today to discuss the matter. They will subsequently meet orthopaedic implant manufacturers this week. Both these categories of devices are under the pricing regulator's radar to bring them under price control. Capping prices of coronary stents was the first move in slashing prices of medical devices. In February this year, the regulator slashed the prices of coronary stents by 85 per cent. This event ... image
Business Standard
177 22